Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

Cancer

Volumn 107, Issue 12, 2006, Pages 2842-2849

  Ardizzoni, Andrea ^a   Cafferata, Mara A ^b   Tiseo, Marcello ^a   Filiberti, Rosangela ^b   Marroni, Paola ^b   Grossi, Francesco ^b   Paganuzzi, Michela ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Carcinoembryonic antigen; Cytokeratin 19 fragment; Nonsmall cell lung cancer; Predictive factor; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KERATIN-19; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33845570605     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22330     Document Type: Article

References (21)

1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22:330-353.
2. Paesmans M, Sculier JP, Libert P, et al. Response to chemotherapy has predictive value for further survival of patients with advanced non-small-cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer. 1997;33:2326-2332.
3. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002; 20:1335-1343.
4. Lieberman R. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am J Ther. 2004;11:501-506.
5. Meyer T, Rustin GJS. Role of tumor markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82:1535-1538.
6. Trape J, Buxo J, Perez de Olaguer J, Vidal C. Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res. 2003;23:4277-4281.
7. Kasimir-Bauer S, Schleucher N, Weber R, Neumann R, Seeber S. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival. Oncol Rep. 2003;10:475-482.
8. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer. 2004;90: 2097-2105.
9. Muley T, Dienemann H, Ebert W. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res. 2004;24:1953-1956.
10. Barlesi F, Gimenez C, Torre JP, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small-cell lung cancer. Respir Med. 2004;98: 357-362.
11. Molina R, Filella X, Auge JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small-cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 2003;24:209-218.
12. Stieber P Zimmermann A, Reinmiedl J, Muller C, Hoffmann H, Dienemann H. CYFRA 21-1 in the early diagnosis of recurrent disease in non-small-cell lung carcinomas (NSCLC). Anticancer Res. 1999;19:2665-2668.
13. Giovanella L, Ceriani L, Bandera M, Beghe B, Roncari G. Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer. Int J Biol Markers. 1995;10:156-160.
14. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver-operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
15. van der Gaast A, Schoenmakers CH, Kok TC, Blijenberg BG, Cornillie F, Splinter TA. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br J Cancer. 1994;69:525-528.
16. Hamzaoui A, Thomas P, Castelnau O, Roux N, Roux F, Kleisbauer JP. Usefulness of longitudinal evaluation of Cyfra 21-1 variations in advanced lung cancer monitoring. Lung Cancer. 1997;16:191-202.
17. Vollmer RT, Govindan R, Graziano SL, et al. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res. 2003;9:1728-1733.
18. Holdenrieder S, Stieber P, von Pawel I, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:5981-5987.
19. Merle P, Janicot H, Filaire M, et al. Early CYFRA 21-1 variation predicts tumor response to chemotherapy and survival in locally advanced non-small cell lung cancer patients. Int J Biol Markers. 2004;19:310-315.
20. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657.
21. 18F] Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005; 23:1136-1143.